Capitolis Liquid Global Markets LLC Boosts Stake in Johnson & Johnson $JNJ

Capitolis Liquid Global Markets LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 478.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 219,911 shares of the company’s stock after purchasing an additional 181,911 shares during the quarter. Capitolis Liquid Global Markets LLC’s holdings in Johnson & Johnson were worth $45,511,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Catalio Capital Management LP purchased a new stake in Johnson & Johnson in the 4th quarter worth about $25,008,000. Claro Advisors Inc. raised its position in Johnson & Johnson by 1.6% in the 4th quarter. Claro Advisors Inc. now owns 21,619 shares of the company’s stock worth $4,474,000 after purchasing an additional 340 shares during the period. Clay Northam Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $217,000. Concentric Capital Strategies LP raised its position in Johnson & Johnson by 851.3% in the 4th quarter. Concentric Capital Strategies LP now owns 28,235 shares of the company’s stock worth $5,843,000 after purchasing an additional 25,267 shares during the period. Finally, Core Wealth Partners LLC raised its position in Johnson & Johnson by 0.4% in the 4th quarter. Core Wealth Partners LLC now owns 11,994 shares of the company’s stock worth $2,482,000 after purchasing an additional 46 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $233.44 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The firm’s 50 day moving average price is $231.07 and its 200-day moving average price is $227.93. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The company has a market cap of $561.95 billion, a PE ratio of 26.99, a P/E/G ratio of 2.30 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period last year, the firm earned $2.77 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s payout ratio is 61.97%.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Citigroup upped their target price on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Finally, Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.